BioNTech's Cancer Drug Gets FDA Fast Track
Ticker: BNTX · Form: 6-K · Filed: Jun 24, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: drug-designation, oncology, FDA, collaboration
Related Tickers: BNTX
TL;DR
BioNTech's cancer drug DB-1305 gets FDA Fast Track for HER2+ breast cancer.
AI Summary
On June 24, 2024, BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to their investigational antibody-drug conjugate, hit-to-lead candidate DB-1305, for the treatment of patients with advanced or metastatic HER2-positive breast cancer. This designation is intended to expedite the development and review of drugs for serious conditions.
Why It Matters
The FDA's Fast Track designation for DB-1305 could accelerate the development and potential approval of a new treatment option for HER2-positive breast cancer patients, offering hope for improved outcomes.
Risk Assessment
Risk Level: medium — While Fast Track designation is positive, the drug is still investigational and faces significant clinical development and regulatory hurdles before potential market approval.
Key Players & Entities
- BioNTech SE (company) — Registrant and collaborator
- Duality Biologics (Suzhou) Co., Ltd. (company) — Collaborator
- U.S. Food and Drug Administration (company) — Regulatory body granting designation
- DB-1305 (drug) — Investigational antibody-drug conjugate
- June 24, 2024 (date) — Date of announcement
FAQ
What is the specific indication for which DB-1305 received Fast Track designation?
DB-1305 received Fast Track designation for the treatment of patients with advanced or metastatic HER2-positive breast cancer.
Who are the companies involved in the development of DB-1305?
BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. are involved in the development of DB-1305.
What is the significance of the Fast Track designation granted by the FDA?
The Fast Track designation is intended to expedite the development and review of drugs for serious conditions, potentially leading to earlier market access.
What type of drug is DB-1305?
DB-1305 is an investigational antibody-drug conjugate.
When was the Fast Track designation announced?
The Fast Track designation was announced on June 24, 2024.
Filing Stats: 273 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-06-24 08:07:43
Filing Documents
- form6-kbnt324fasttrack24ju.htm (6-K) — 15KB
- ex991bnt324fast-track24jun.htm (EX-99.1) — 29KB
- image_0.jpg (GRAPHIC) — 42KB
- image_1.jpg (GRAPHIC) — 7KB
- 0001776985-24-000057.txt ( ) — 113KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On June 24, 2024, BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. announced that the U.S. Food and Drug Administration granted Fast Track designation for BNT324DB-1311 for the treatment of patients with advancedunresectable, or metastatic castration–resistant prostate cancer who have progressed on or after standard systemic regimens. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Jens Holstein By s Dr. Sierk Poetting Name Jens Holstein Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date June 24, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324DB-1311 in Prostate Cancer